CVM

Cel-Sci Corp

1.45

Nov 06 • 3:58 PM ET +0.08 (5.84%)

1.45

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Nano AMEX

Peers: PDSB IMMP IMNN AIM BCTX SLS GLSI ELTX MAIA INMB

| Held by: VTI VXF BUSM

Scroll to Statements

Index	-
Market Cap	25.50M
Enterprise Value	26.87M
Income	-22.70M
Sales	0.00M
Book/sh	0.62
Cash/sh	0.37
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Dec 08, 1983

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.33
P/C	3.91
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.42
Current Ratio	1.48
Debt/Eq	0.72
LT Debt/Eq	0.47
Option/Short	No / Yes

EPS (ttm)	-2.58
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	37.90% 23.99%
Sales past 3/5Y	- -
EPS Y/Y TTM	73.69%
Sales Y/Y TTM	-
EPS Q/Q	65.72%
Sales Q/Q	-
Earnings	Aug 17 BMO
EPS/Sales Surpr.	- -

Insider Own	6.94%
Insider Trans	69.36%
Inst Own	12.04%
Inst Trans	9.45%
ROA	-108.91%
ROE	-252.53%
ROIC	-140.57%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.79%
SMA50	-14.23%
SMA200	-39.95%
Trades

Shs Outstand	17.59M
Shs Float	16.37M
Short Float	4.06%
Short Ratio	3.59
Short Interest	0.66M
52W High	7.80 -81.41%
52W Low	0.89 62.92%
Volatility	10.08% 9.23%
ATR (14)	0.16
RSI (14)	42.62
Beta	0.61
Rel Volume	0.25
Avg Volume	184.79K
Volume	46,678

Perf Week	5.07%
Perf Month	-25.64%
Perf Quarter	-2.68%
Perf Half Y	-14.71%
Perf YTD	-72.43%
Perf Year	-78.16%
Perf 3Y	-97.93%
Perf 5Y	-99.60%
Perf 10Y	-99.23%
Recom	1.00
Target Price	10.00
Prev Close	1.37
Price	1.45
Change %	5.84%

Consensus

Strong Buy

Avg. Price Target

$10.00

Implied Upside

+589.7%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 13, 2020	Initiated	HH.C. Wainwright	Buy	$18	+1,141.4%
Mar 02, 2015	Initiated	DDawson James	Buy	$3	+106.9%

Oct-26-26 08:00AM	CEL-SCI Presents New Phase 3 Multikine Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival (Business Wire)
Sep-15-26 08:37AM	CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology (Business Wire)
Aug-17-26 08:30AM	CEL-SCI Reports Fiscal Third Quarter 2026 Results (Business Wire)
Aug-14-26 05:16PM	Cel-Sci: Fiscal Q3 Earnings Snapshot (Associated Press)
Aug-04-26 08:00AM	CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study (Business Wire) +8.80%
08:31AM	Loading…
Jul-30-26 08:31AM	Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients (Business Wire) +7.02%
Jun-15-26 07:12AM	CVM Stock Sinks In Pre-Market Trading After Announcing Second Equity Raise For Its Cancer Drug In Just Over A Month (Stocktwits) -6.48%
May-15-26 05:32PM	Cel-Sci: Fiscal Q2 Earnings Snapshot (Associated Press) +10.00% +20.28%
Feb-17-26 05:14PM	Cel-Sci: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +8.37%
Oct-20-25 09:00AM	CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025 (TMX Newsfile)
Oct-10-25 08:00AM	CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference (TMX Newsfile)
Aug-14-25 10:45AM	CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results (Business Wire)
09:37AM	Cel-Sci: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Aug-13-25 09:15AM	CEL-SCIs Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline (Business Wire) +9.44%
Jul-14-25 04:05PM	CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules (Business Wire)
12:16PM	Loading…
Jul-11-25 12:16PM	CEL-SCI Announces Pricing of $5.7 Million Offering Priced At-the-Market Under NYSE American Rules (Business Wire) -7.59%
09:15AM	CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer (Business Wire)
Jun-18-25 09:00AM	FDAs Approval of Keytruda for PD-L1 Positive Head and Neck Cancer Patients Signals a Clear Pathway for CEL-SCIs Multikine to Address a Major Unmet Need in PD-L1 Negative Cancer Patients (Business Wire)
May-23-25 04:05PM	CEL-SCI Announces Closing of Public Offering (Business Wire)
May-21-25 08:14PM	CEL-SCI Announces Pricing of Public Offering (Business Wire) -11.74% -45.45%
04:05PM	CEL-SCI Announces Proposed Public Offering (Business Wire)
08:00AM	CEL-SCIs Multikine Investigational Cancer Medicine Potentially Available for Commercialization by Summer 2025 in Saudi Arabia (Business Wire)
May-19-25 02:40PM	CEL-SCI Announces Combination of Common Stock (Business Wire) -8.61%
May-15-25 09:00AM	CEL-SCI Reports Fiscal Second Quarter 2025 Financial Results (Business Wire)
May-14-25 07:30PM	Cel-Sci: Fiscal Q2 Earnings Snapshot (Associated Press Finance) -6.84%
Apr-23-25 08:30AM	CEL-SCI to File for Regulatory Approval of Multikine in Saudi ArabiaPursuing Local Partnerships for Commercialization and Manufacturing to Serve Middle East and North Africa Market (Business Wire) +5.20%
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire) -21.86%
Apr-08-25 09:51AM	New Study in the Scientific Journal "Cancer Cell" Supports CEL-SCIs Strategy to Seek Early Approval for Multikine in Head and Neck Cancer Based on Pre-Surgical Tumor Responses (Business Wire) -8.29%
Mar-24-25 09:00AM	CEL-SCI Reports New Data: Treatment with Multikine Resulted in up to 95% Improvement in Quality of Life for Head and Neck Cancer Patients (Business Wire)
Mar-18-25 04:05PM	CEL-SCI Announces Closing of $2.5 Million Offering (Business Wire) +5.24%
03:24PM	Loading…
Mar-17-25 03:24PM	CEL-SCI Announces Pricing of $2.5 Million Offering (Business Wire) -6.55%
08:00AM	CEL-SCIs Head and Neck Cancer Registration Study Protocol Clears FDA Reviewin Talks with Potential Partners Interested in Commercialization of Multikine (Business Wire)
Mar-14-25 08:30AM	Journal of the American Medical Association (JAMA) Study Provides Further Evidence that CEL-SCIs Multikine Can Treat Unmet Need in ~70% of Head and Neck Patients Based on PD-L1 Expression (Business Wire)
Feb-20-25 08:00AM	CEL-SCI to Initiate Multikine Confirmatory Phase 3 Cancer Trial (Business Wire) -17.50%
Feb-18-25 08:30AM	CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks (Business Wire) +6.91%
Feb-14-25 04:24PM	Cel-Sci: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Jan-14-25 09:00AM	CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer (Business Wire)
Dec-31-24 04:05PM	CEL-SCI Announces Closing of $5 Million Offering (Business Wire)
Dec-29-24 08:41PM	CEL-SCI Announces Pricing of $5 Million Public Offering (Business Wire)
Dec-27-24 05:05PM	CEL-SCI Announces Proposed Public Offering of Common Stock (Business Wire) -14.87% -32.26%
Dec-12-24 09:15AM	CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study (Business Wire) +10.86%
Nov-07-24 08:15AM	U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025 (Business Wire) -7.92%
Oct-22-24 09:15AM	FDAs Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCIs Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients (Business Wire)
Oct-01-24 06:00AM	CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer (Business Wire)
Sep-16-24 07:30AM	CEL-SCIs Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation (Business Wire) -10.16%
Sep-10-24 09:32AM	CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress (Business Wire)
Sep-04-24 09:00AM	The UKs Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance (Business Wire)
Aug-15-24 08:00AM	CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results (Business Wire)
05:09AM	Cel-Sci: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
Jul-29-24 04:05PM	CEL-SCI Announces Closing of $10.8 Million Offering (Business Wire) -5.34%
Jul-26-24 11:52AM	CEL-SCI Announces Pricing of $10.8 Million Offering (Business Wire) +8.26%
08:23AM	CEL-SCIs Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results (Business Wire)
Jul-08-24 09:15AM	CEL-SCI Appoints Robert Watson as Chairperson of the Board (Business Wire)
Jun-18-24 08:00AM	CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population (Business Wire) -11.20%
Jun-06-24 07:00AM	Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor (Business Wire)
May-16-24 09:08AM	Cel-Sci: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
09:00AM	CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results (Business Wire)
May-08-24 04:02PM	Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine (MT Newswires) -16.77% +8.63%
09:00AM	CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer (Business Wire)
Apr-23-24 09:00AM	CEL-SCI Appoints Mario Gobbo to Its Board of Directors (Business Wire)
Mar-19-24 09:00AM	CEL-SCIs LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology (Business Wire)
Mar-06-24 08:45AM	CEL-SCI Corporation Issues Letter to Shareholders (Business Wire) +8.07%
Feb-15-24 08:00AM	CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results (Business Wire)
Feb-14-24 05:11PM	Cel-Sci: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
Feb-13-24 12:00PM	CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock (Business Wire)
Feb-09-24 08:30AM	CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock (Business Wire) -13.68%
Feb-06-24 09:00AM	CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug (Business Wire) +5.48%
Jan-31-24 09:00AM	European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® (Business Wire)
Dec-22-23 08:00AM	CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments (Business Wire)
Dec-04-23 08:30AM	UKS National Institute for Health and Care Excellence (NICE) Selects CEL-SCIs Multikine as Potential New Standard of Care for Head & Neck Cancer (Business Wire) +35.27%
Nov-20-23 04:15PM	CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock (Business Wire) +11.01%
Nov-16-23 08:30AM	CEL-SCI Announces Pricing of $5 Million Offering of Common Stock (Business Wire) -22.57%
Nov-09-23 08:52AM	12 Best Day Trading Stocks To Buy (Insider Monkey) -6.27%
Oct-30-23 09:20AM	CEL-SCI Issues Letter to Shareholders (Business Wire) +8.26%
Oct-24-23 08:00AM	CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals (Business Wire)
Oct-23-23 09:15AM	5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCIs Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023 (Business Wire) +41.12%
Oct-19-23 08:00AM	CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production (Business Wire)
Oct-09-23 07:50AM	CVM: Regulatory Journey Accelerating (Zacks) -5.04%
Oct-05-23 08:45AM	CEL-SCI Files Request With the UKs MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer (Business Wire) -6.03%
Sep-26-23 09:00AM	CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer (Business Wire)
Aug-11-23 08:07AM	Cel-Sci: Fiscal Q3 Earnings Snapshot (Associated Press Finance) -12.68%
08:00AM	CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results (Business Wire)
Jul-31-23 05:49AM	CVM: Model Revisions (Zacks)
Jul-20-23 11:36AM	CEL-SCI Announces Closing of Public Offering (Business Wire) -8.80%
Jul-17-23 09:23PM	CEL-SCI Announces Pricing of Public Offering (Business Wire) +11.72% -23.43%
04:05PM	CEL-SCI Announces Proposed Public Offering of Common Stock (Business Wire)
Jul-14-23 09:15AM	CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikines Approval for Head & Neck Cancer (Business Wire) +9.40%
Jul-11-23 08:45AM	CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikines Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer (Business Wire)
Jun-22-23 10:19AM	CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck CancerNew Patent to Be Filed (Business Wire)
May-16-23 09:17AM	CVM: Health Canada Conditional Approval (Zacks Small Cap Research)
May-15-23 02:18PM	Why CEL-SCI Shares Are Shooting Higher Today (Benzinga) +8.33%
09:00AM	Histopathology and Tumor Biomarker Analysis Confirm CEL-SCIs Multikine Significantly Prolonged Overall Survival in Head & Neck CancerPhase 3 Data Presented at ESTRO 2023 (Business Wire)
May-12-23 04:35PM	Cel-Sci: Fiscal Q2 Earnings Snapshot (AP Finance) -11.44%
04:30PM	CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results (Business Wire)
Apr-27-23 09:12PM	CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock (Business Wire)
Apr-19-23 09:00AM	CEL-SCI to Pursue Canadas Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer (Business Wire) +15.04%
Mar-08-23 09:00AM	CEL-SCIs Multikine Phase 3 Cancer Study Shows 43% Survival Extension (Business Wire) -5.19%
Mar-03-23 09:00AM	CEL-SCI to Present New Phase 3 Data at European Congress on Head & Neck Oncology (Business Wire) +26.50%
Feb-27-23 05:26AM	CVM: BLA Filing Still on the Horizon (Zacks Small Cap Research)
Feb-15-23 09:00AM	CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KERSTEN GEERT R	Chief Executive Officer	Aug 25 '26	Buy	1.38	100,000	138,000	316,142	Aug 26 08:32 AM
KERSTEN GEERT R	Chief Executive Officer	May 14 '26	Buy	1.20	300,000	360,000	311,547	May 18 08:03 AM
KERSTEN GEERT R	Chief Executive Officer	May 13 '26	Buy	1.19	100,000	119,000	222,497	May 14 08:56 AM
KERSTEN GEERT R	Chief Executive Officer	Jan 22 '26	Buy	5.26	38,023	200,001	120,815	Jan 26 08:23 AM
KERSTEN GEERT R	Chief Executive Officer	Dec 04 '25	Buy	5.96	8,389	49,998	81,794	Dec 05 08:48 AM

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients and CEL-2000 and CEL-4000, which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

CEOMr. Geert R. Kersten Esq.

Chief Financial & Operations OfficerMs. Patricia B. Prichep

Chief Scientific OfficerDr. Eyal Talor Ph.D.

Senior Vice President of Regulatory AffairsMr. John Cipriano

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CVM

Cel-Sci Corp

Upgrade your Finviz experience